In this study, although insulin and/or metformin were not informative enough to be included in the multivariate assessment of the likelihood of death, the information about their administration revealed a contrast in how remdesivir and LMWH (in the case of metformin) compared to hsCRP and age (in the case of insulin) affected the odds of death in hospitalized T2DM patients suffering from COVID-19. This evidence concerns the gene INS and type 2 diabetes mellitus.